Economy/Home · Economy

[Breaking] SK Biopharmaceuticals Signs 71.59 Billion Won Drug Supply Contract with Subsidiary... Epilepsy New Drug XCOPRI to Be Sold in the U.S.

SK Biopharmaceuticals announced on the 14th that it has signed a pharmaceutical supply contract worth 71,593,160,000 won with its subsidiary SK Life Science, Inc. The contract amount is 71,593,161,451 won, equivalent to 10.1% of the company's consolidated revenue for fiscal year 2025 (706,740,960,0

Oseong Kwon
Staff Reporter
3 min read
[Breaking] SK Biopharmaceuticals Signs 71.59 Billion Won Drug Supply Contract with Subsidiary... Epilepsy New Drug XCOPRI to Be Sold in the U.S.
CBC News

SK Biopharmaceuticals announced on the 14th that it has signed a pharmaceutical supply contract worth 71,593,160,000 won with its subsidiary SK Life Science, Inc.

The contract amount is 71,593,161,451 won, equivalent to 10.1% of the company's consolidated revenue for fiscal year 2025 (706,740,960,000 won). The total contract value is 53,173,768.16 U.S. dollars (USD), and the company calculated the won-denominated contract amount by applying the exchange rate of 1,346.40 won per dollar as of the contract date, September 14. No separate value-added tax applies.

The contract is for the sale of cenobamate (product name XCOPRI®), a new drug for treating epilepsy, in the U.S. market. SK Biopharmaceuticals will supply the product to SK Life Science, Inc., its local U.S. subsidiary. However, as it is an internal transaction with a subsidiary, it will not be reflected in revenue on a consolidated financial statement basis.

The key terms of the contract are as follows.

▲Contract period: from September 14 to 18, 2026 ▲Sales and supply region: locations designated by SK Life Science, Inc. ▲Payment: within 120 days of delivery ▲Contract deposit and advance payment: none

Meanwhile, the contract date is September 14, based on the approval date of the Purchase Order.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.